 Halozyme Therapeutics Inc. | HALO | $7.95B | May 2026 | Halozyme First Quarter 2026 Financial & Operating Results | — |
 Braveheart Bio | PVT | — | May 2026 | Braveheart Bio website | Source↗ |
 Isomorphic Labs | PVT | — | May 2026 | Isomorphic Labs website | Source↗ |
 Kardigan | PVT | — | May 2026 | Kardigan website | Source↗ |
 Kriya Therapeutics | PVT | — | May 2026 | Kriya Therapeutics website | Source↗ |
 Revolution Medicines | RVMD | $33.24B | May 2026 | Revolution Medicines Corporate Presentation | Source↗ |
 Sarepta Therapeutics Inc. | SRPT | $1.89B | May 2026 | Sarepta First Quarter 2026 Financial Results | Source↗ |
 Syremis Therapeutics | PVT | — | May 2026 | Syremis Therapeutics website | Source↗ |
 Tubulis | PVT | — | May 2026 | Tubulis website | Source↗ |
 Vaxcyte Inc. | PCVX | $7.42B | May 2026 | Vaxcyte Corporate Presentation | Source↗ |
 Verdiva Bio | PVT | — | May 2026 | Verdiva Bio website | Source↗ |
 Aerska | PVT | — | May 2026 | Aerska website | Source↗ |
 Arcus Biosciences Inc. | RCUS | $3.19B | May 2026 | Arcus Biosciences 1Q26 Corporate Presentation | Source↗ |
 Beeline Medicines | PVT | — | May 2026 | Beeline Medicines website | Source↗ |
 Coultreon Biopharma | PVT | — | May 2026 | Coultreon Biopharma website | Source↗ |
 Cytokinetics Inc. | CYTK | $10.43B | May 2026 | Cytokinetics Corporate Presentation May 2026 | Source↗ |
 Mediar Therapeutics | PVT | — | May 2026 | Mediar Therapeutics website | Source↗ |
 Neurocrine Biosciences Inc. | NBIX | $15.94B | May 2026 | Neurocrine Q1 2026 Earnings Presentation | Source↗ |
 TRexBio | PVT | — | May 2026 | TRexBio website | Source↗ |
 Vertex Pharmaceuticals Inc. | VRTX | $113.71B | May 2026 | Vertex Q1 2026 Earnings Presentation | Source↗ |
 QuantX Biosciences | PVT | — | May 2026 | QuantX Biosciences website | Source↗ |
 Ardelyx | ARDX | $1.51B | May 2026 | Ardelyx Corporate Presentation — May 2026 | Source↗ |
 Kailera Therapeutics | KLRA | $2.96B | May 2026 | Corporate Presentation - May 2026 | Source↗ |
 Krystal Biotech Inc. | KRYS | $9.09B | May 2026 | Krystal Biotech Corporate Presentation May 2026 | — |
 Viking Therapeutics | VKTX | $3.79B | May 2026 | Viking Therapeutics Corporate Presentation May 2026 | Source↗ |
 Syndax Pharmaceuticals Inc | SNDX | $1.74B | April 2026 | Syndax First Quarter 2026 Financial Results and Business Update | Source↗ |
 Nuvalent | NUVL | $8.70B | April 2026 | Nuvalent Corporate Overview April 2026 | Source↗ |
 Wave Life Sciences Ltd. | WVE | $1.28B | April 2026 | Wave Life Sciences Corporate Presentation | Source↗ |
 Erasca | ERAS | $3.94B | April 2026 | Erasca Corporate Presentation April 2026 | Source↗ |
 Sagimet Biosciences | SGMT | $446M | April 2026 | Sagimet Biosciences Corporate Presentation — April 2026 | Source↗ |
 BioAge Labs Inc. | BIOA | $767M | April 2026 | BioAge Labs Corporate Presentation | Source↗ |
 Agenus Inc | AGEN | $140M | April 2026 | BOT/BAL Corporate Overview | Source↗ |
 Arcutis Biotherapeutics | ARQT | $2.68B | April 2026 | Arcutis Corporate Presentation — April 2026 | Source↗ |
 Beam Therapeutics | BEAM | $3.44B | April 2026 | Beam Therapeutics Corporate Presentation | Source↗ |
 Belite Bio | BLTE | $5.72B | April 2026 | Belite Bio Corporate Presentation — April 2026 | Source↗ |
 CG Oncology | CGON | $5.46B | April 2026 | CG Oncology Investor Presentation | Source↗ |
 Day One Biopharmaceuticals | DAWN | $2.22B | April 2026 | Day One Corporate Presentation | Source↗ |
 Disc Medicine | IRON | $2.69B | April 2026 | Disc Medicine Corporate Presentation | Source↗ |
 Intellia Therapeutics | NTLA | $1.96B | April 2026 | Intellia Therapeutics Corporate Presentation | Source↗ |
 Maze Therapeutics | MAZE | $1.47B | April 2026 | Maze Therapeutics Corporate Presentation — April 2026 | Source↗ |
 Mirum Pharmaceuticals | MIRM | $6.17B | April 2026 | Mirum Corporate Presentation April 2026 | Source↗ |
 Nektar Therapeutics | NKTR | $2.19B | April 2026 | Nektar Therapeutics Corporate Presentation | Source↗ |
 Ocular Therapeutix | OCUL | $2.02B | April 2026 | Ocular Therapeutix Corporate Overview | Source↗ |
 Relay Therapeutics | RLAY | $3.08B | April 2026 | Relay Therapeutics April 2026 Corporate Presentation | Source↗ |
| Revolution Medicines | RVMD | $33.24B | April 2026 | Revolution Medicines Corporate Presentation | Source↗ |
 Rhythm Pharmaceuticals | RYTM | $6.22B | April 2026 | Rhythm Corporate Presentation April 2026 | Source↗ |
 Tyra Biosciences | TYRA | $2.00B | April 2026 | Tyra Biosciences Investor Presentation | Source↗ |
 Zentalis Pharmaceuticals | ZNTL | $290M | April 2026 | Zentalis Corporate Presentation — April 2026 | Source↗ |
 Vera Therapeutics | VERA | $2.56B | April 2026 | Vera Therapeutics Corporate Deck April 2026 | Source↗ |
 Spyre Therapeutics | SYRE | $6.30B | April 2026 | Spyre Therapeutics Corporate Overview | Source↗ |
 Korsana Biosciences | PVT | — | April 2026 | Korsana Biosciences Corporate Deck April 2026 | Source↗ |
 Cue Biopharma Inc. | CUE | $90M | April 2026 | Cue Biopharma R&D Day Event | Source↗ |
 Jade Biosciences | JBIO | $1.06B | April 2026 | Jade Biosciences Company Presentation — March 2026 | Source↗ |
 Candel Therapeutics Inc. | CADL | $609M | April 2026 | Candel Therapeutics Corporate Presentation | Source↗ |
 Corcept Therapeutics Inc. | CORT | $7.44B | April 2026 | Corcept Therapeutics Investor Presentation | Source↗ |
 Nurix Therapeutics Inc. | NRIX | $1.84B | April 2026 | Nurix Therapeutics Investor Presentation April 2026 | Source↗ |
 Palvella Therapeutics, Inc. | PVLA | $1.69B | April 2026 | Palvella Therapeutics Corporate Presentation April 2026 | Source↗ |
 Phathom Pharmaceuticals Inc. | PHAT | $785M | April 2026 | Phathom Pharmaceuticals Corporate Overview April 2026 | Source↗ |
 Taysha Gene Therapies Inc. | TSHA | $1.69B | April 2026 | Taysha Gene Therapies Corporate Presentation April 2026 | Source↗ |
 Viridian Therapeutics | VRDN | $1.94B | March 2026 | Viridian Corporate Deck March 2026 (REVEAL Update) | Source↗ |
 Apogee Therapeutics | APGE | $6.08B | March 2026 | Apogee Therapeutics Corporate Presentation | Source↗ |
 Insmed Inc. | INSM | $23.23B | March 2026 | Insmed Investor Presentation March 2026 | Source↗ |
 AnaptysBio | ANAB | $1.61B | March 2026 | AnaptysBio Corporate Presentation — April 2026 | Source↗ |
 KalVista Pharmaceuticals | KALV | $1.43B | March 2026 | KalVista Corporate Presentation March 2026 | Source↗ |
 Absci Corp | ABSI | $1.09B | March 2026 | Corporate Presentation March 2026 — Generative AI Drug Creation | Source↗ |
 Amylyx Pharmaceuticals | AMLX | $1.57B | March 2026 | Amylyx Pharmaceuticals Corporate Presentation — March 2026 | Source↗ |
 Compass Pathways plc | CMPS | $1.74B | March 2026 | Transforming Mental Health Care Investor Presentation March 2026 | Source↗ |
 Abivax S.A. | ABVX | $10.56B | March 2026 | Corporate Presentation | Source↗ |
 Avalo Therapeutics Inc. | AVTX | $839M | March 2026 | Avalo Corporate Presentation March 2026 | Source↗ |
 Celldex Therapeutics Inc. | CLDX | $2.48B | March 2026 | Pioneering new horizons in immunology to deliver life-changing therapies | Source↗ |
 Bicycle Therapeutics plc | BCYC | $331M | March 2026 | Bicycle Therapeutics Corporate Presentation | Source↗ |
 Harrow | HROW | $1.31B | March 2026 | Harrow Corporate Presentation — March 2026 | Source↗ |
 Immunome | IMNM | $2.51B | March 2026 | Immunome Corporate Presentation — March 2026 | Source↗ |
 Novavax | NVAX | $1.82B | March 2026 | Novavax Corporate Presentation — March 2026 | Source↗ |
 Vericel | VCEL | $1.72B | March 2026 | Vericel Corporate Presentation — March 2026 | Source↗ |
 Oruka Therapeutics | ORKA | $3.52B | March 2026 | Oruka Therapeutics Corporate Overview — March 2026 | Source↗ |
 Boundless Bio Inc. | BOLD | $32M | March 2026 | Corporate Presentation March 2026 | Source↗ |
 IDEAYA Biosciences | IDYA | $2.62B | March 2026 | IDEAYA Corporate Deck March 2026 | Source↗ |
 Compass Therapeutics Inc. | CMPX | $435M | March 2026 | Corporate Presentation | Source↗ |
 Agomab Therapeutics NV | AGMB | $556M | March 2026 | Agomab Investor Presentation | Source↗ |
 Alector Inc. | ALEC | $247M | March 2026 | Alector Corporate Presentation | Source↗ |
 Alumis Inc. | ALMS | $2.75B | March 2026 | Alumis Corporate Presentation | Source↗ |
 argenx SE | ARGX | $52.07B | March 2026 | argenx Corporate Presentation March 2026 | Source↗ |
 Oric Pharmaceuticals Inc. | ORIC | $902M | March 2026 | ORIC Pharmaceuticals Company Presentation March 2026 | Source↗ |
 Terns Pharmaceuticals | TERN | $6.12B | March 2026 | Terns Corporate Presentation March 2026 | Source↗ |
 Trevi Therapeutics, Inc. | TRVI | $2.04B | March 2026 | Trevi Therapeutics Corporate Presentation March 2026 | Source↗ |
 UroGen Pharma Ltd. | URGN | $1.37B | March 2026 | UroGen Corporate Presentation March 2026 | Source↗ |
 Vor Bio Inc. | VOR | $813M | March 2026 | Vor Bio Corporate Presentation March 2026 | Source↗ |
 Zymeworks Inc. | ZYME | $1.85B | March 2026 | Zymeworks Corporate Deck March 2026 | Source↗ |
 BioMarin Pharmaceutical | BMRN | $10.74B | February 2026 | BioMarin Q4 2025 Earnings Presentation | Source↗ |
 Corvus Pharmaceuticals Inc. | CRVS | $1.03B | February 2026 | Corvus Pharmaceuticals Corporate Presentation | Source↗ |
 Recursion Pharmaceuticals | RXRX | $1.89B | February 2026 | Recursion 4Q & FY 2025 Corporate Presentation | Source↗ |
 Zai Lab Ltd | ZLAB | $2.00B | February 2026 | Zai Lab Corporate Presentation | Source↗ |
 Kymera Therapeutics | KYMR | $6.74B | February 2026 | Kymera Therapeutics Corporate Presentation — February 2026 | Source↗ |
 AbCellera Biologics Inc. | ABCL | $1.87B | February 2026 | Full Year 2025 Business Update | — |
 Apellis Pharmaceuticals Inc. | APLS | $5.26B | February 2026 | Fourth Quarter and Full Year 2025 Financial Results | — |
 BridgeBio Pharma Inc. | BBIO | $13.11B | February 2026 | BridgeBio Corporate Presentation February 2026 | Source↗ |
 Praxis Precision Medicines | PRAX | $9.55B | February 2026 | Praxis February 2026 Corporate Presentation | Source↗ |
 Soleno Therapeutics | SLNO | $2.76B | February 2026 | Soleno Therapeutics February 2026 Corporate Presentation | Source↗ |
 Crinetics Pharmaceuticals | CRNX | $3.76B | February 2026 | Crinetics Corporate Presentation February 2026 | Source↗ |
 Immutep | IMMP | $65M | February 2026 | Immutep Corporate Presentation — February 2026 | Source↗ |
 Immunovant | IMVT | $6.84B | February 2026 | Immunovant Master Deck February 2026 | Source↗ |
 SELLAS Life Sciences | SLS | $1.76B | February 2026 | SELLAS Life Sciences Corporate Presentation — February 2026 | Source↗ |
 Aurinia Pharmaceuticals Inc. | AUPH | $1.95B | February 2026 | Aurinia Corporate Presentation February 2026 | Source↗ |
 Bicara Therapeutics Inc. | BCAX | $1.44B | February 2026 | Bicara Therapeutics Corporate Presentation | Source↗ |
 Geron Corporation | GERN | $802M | February 2026 | Geron Corporate Presentation February 2026 | Source↗ |
 MoonLake Immunotherapeutics | MLTX | $1.41B | February 2026 | MoonLake Investor Day February 2026 | Source↗ |
| Halozyme Therapeutics Inc. | HALO | $7.95B | January 2026 | Halozyme Guidance and Business Update January 2026 | — |
 Elicio Therapeutics | ELTX | $215M | January 2026 | Elicio Therapeutics Corporate Deck — January 2026 | Source↗ |
 CytomX Therapeutics Inc. | CTMX | $790M | January 2026 | CytomX Therapeutics JP Morgan 2026 | Source↗ |
 Ascendis Pharma A/S | ASND | $13.79B | January 2026 | Ascendis Pharma Corporate Presentation | Source↗ |
 CRISPR Therapeutics | CRSP | $5.37B | January 2026 | CRISPR Therapeutics J.P. Morgan 2026 | Source↗ |
 Denali Therapeutics | DNLI | $3.36B | January 2026 | DNLI Corporate Presentation — January 2026 | Source↗ |
 Enliven Therapeutics | ELVN | $2.43B | January 2026 | Enliven Non-Confidential Overview JPM 2026 | Source↗ |
 Nuvation Bio | NUVB | $1.65B | January 2026 | Nuvation Bio Corporate Presentation — January 2026 | Source↗ |
 Scholar Rock | SRRK | $5.98B | January 2026 | Scholar Rock January 2026 Corporate Presentation | Source↗ |
 Stoke Therapeutics Inc. | STOK | $1.93B | January 2026 | Stoke Therapeutics JP Morgan 2026 | Source↗ |
 Structure Therapeutics | GPCR | $2.81B | January 2026 | Structure Therapeutics Corporate Presentation January 2026 | Source↗ |
 Alnylam Pharmaceuticals Inc. | ALNY | $40.09B | January 2026 | Alnylam 2026 J.P. Morgan Presentation | Source↗ |
| Apellis Pharmaceuticals Inc. | APLS | $5.26B | January 2026 | 44th Annual J.P. Morgan Healthcare Conference | — |
 Summit Therapeutics | SMMT | $13.83B | January 2026 | Summit Therapeutics J.P. Morgan 2026 Investor Deck | Source↗ |
 Travere Therapeutics | TVTX | $4.38B | January 2026 | Travere Therapeutics Corporate Overview January 2026 | Source↗ |
 uniQure N.V. | QURE | $1.78B | January 2026 | uniQure Corporate Presentation January 2026 | Source↗ |
 Arcellx | ACLX | $6.73B | January 2026 | Arcellx January 2026 Corporate Presentation | Source↗ |
 Axsome Therapeutics Inc. | AXSM | $11.99B | January 2026 | Axsome Therapeutics Corporate Presentation | Source↗ |
 Biohaven Ltd. | BHVN | $1.69B | January 2026 | Biohaven Corporate Presentation January 2026 | Source↗ |
 Incyte Corporation | INCY | $19.48B | January 2026 | Incyte Corporate Presentation | Source↗ |
 Ionis Pharmaceuticals Inc. | IONS | $12.76B | January 2026 | Ionis Corporate Presentation | Source↗ |
 Jazz Pharmaceuticals plc | JAZZ | $14.68B | January 2026 | Jazz Pharmaceuticals Corporate Overview | Source↗ |
 Lantheus Holdings Inc. | LNTH | $6.53B | January 2026 | Lantheus Investor Presentation | Source↗ |
 Monte Rosa Therapeutics Inc. | GLUE | $1.65B | January 2026 | Monte Rosa Therapeutics JP Morgan 2026 | Source↗ |
 Regeneron Pharmaceuticals Inc. | REGN | $64.47B | January 2026 | Regeneron Investor Presentation | Source↗ |
 Legend Biotech Corporation | LEGN | $5.04B | November 2025 | Legend Biotech Q3 2025 Corporate Update | Source↗ |
 Ventyx Biosciences | VTYX | $1.20B | October 2025 | Ventyx Corporate Presentation | Source↗ |
 Madrigal Pharmaceuticals Inc. | MDGL | $11.57B | October 2025 | Madrigal Q3 2025 Presentation | Source↗ |
| AbCellera Biologics Inc. | ABCL | $1.87B | August 2025 | AbCellera Corporate Overview | Source↗ |
| Sarepta Therapeutics Inc. | SRPT | $1.89B | January 2025 | Sarepta Corporate Presentation 2025 | Source↗ |